Colleague

There is no image.

Treatment option:

Medically reviewed

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Colleague

What is Colleague? Definitive Overview

Property	Description
Active Ingredients	Albendazole, Pyraclofos
Form	Tablet, Oral Suspension
Pharmacological Class	Broad-spectrum Anthelmintic
Origin	Synthetic

What Type of Medicine is Colleague (Albendazole/Pyraclofos)?

Colleague is a synthetic combination drug classified as a broad-spectrum anthelmintic medicine, specifically engineered to eliminate various parasitic organisms from the body. It represents a dual-component product that leverages the actions of two distinct active pharmaceutical ingredients. The medicine is administered via the oral route, targeting internal infestations with a comprehensive approach. The use of its core component, Albendazole, is clinically recognized for its efficacy in mass drug administration programs aimed at reducing the global burden of parasitic diseases. This medicine contains a core ingredient recognized for its role in fighting parasitic diseases. Unlike single-agent drugs, this formulation is designed to engage two separate and complementary physiological actions, establishing its unique identity within the anti-parasitic class.

Composition and Available Forms of Colleague

The therapeutic action of Colleague rests upon its two primary active ingredients, Albendazole and Pyraclofos, integrated into standard oral dosage form(s). The medicine is typically available as a conventional tablet or an oral suspension, often positioned for use in adult and pediatric patient groups due to its availability in liquid form. Albendazole belongs to the well-established benzimidazole class of anti-parasitic drugs, while Pyraclofos provides an additional, distinct mechanism of action. Albendazole is chemically defined as Methyl 5-(propylthio)-2-benzimidazolecarbamate, confirming its synthetic origin. The remainder of the preparation consists of an inert base and excipients necessary for product stability and appropriate oral delivery.

General Purpose of This Combination Anthelmintic

The general purpose of this combination medicine is to provide a robust anti-parasitic strategy aimed at controlling and clearing infestations caused by a wide variety of parasitic worms and related organisms. A typical neutral use scenario for Colleague involves clearing infections that require a broader scope of activity than a single drug can provide, often serving as a reliable intervention against multiple concurrent infestations. The drug's dual-mechanism approach works by simultaneously interfering with the parasite's ability to maintain its internal structure and metabolism while also disrupting its neurological functions. This strategic, two-pronged attack leads to the rapid demise and subsequent clearance of the causative organisms. This comprehensive action is the core benefit, positioning Colleague as a powerful option for addressing infections where broad-spectrum activity is required.

What side effects are possible with Colleague?

Possible Side Effects and Safety Information

The safety characteristics of Colleague are derived primarily from its main active component, which is classified in regulatory documents by the frequency and organ system involved. This information is designed to communicate the officially documented risk profile of the medicine.

Adverse Reaction Classifications

Side effects are officially classified into frequency tiers, based on clinical data from regulatory submissions. Effects classified as Very Common (ge 10%) can include elevated hepatic enzymes in certain uses and headache, while Common (1-10%) reactions often involve mild gastrointestinal symptoms (such as abdominal pain, nausea, and vomiting), dizziness, and reversible alopecia.

Adverse reactions are further grouped by System-Organ-Classes (SOC) which include Hepatobiliary Disorders, Blood and Lymphatic System Disorders, and Nervous System Disorders. Gastrointestinal effects are commonly reported within the official safety data.

Serious Adverse Reactions and Safety Constraints

Official regulatory documents cite rare but clinically significant adverse reactions. These documented Serious Adverse Reactions include potentially fatal conditions such as Aplastic Anemia and other forms of severe Bone Marrow Suppression (Pancytopenia, Agranulocytosis), as well as Acute Liver Failure and severe skin reactions like Stevens-Johnson syndrome.

Safety constraints define specific conditions for use. The medicine is contraindicated in females who are pregnant due to evidence of embryo-fetal toxicity. Furthermore, individuals with pre-existing hepatic impairment require increased monitoring due to a higher documented risk of hepatotoxicity and bone marrow suppression. For patients being treated for neurocysticercosis, specific time-related patterns note that severe neurological symptoms may arise following the initiation of therapy.

Overdose and Emergency Response

Overdose and When to Seek Help

This section details the officially documented manifestations and required emergency actions for an overdose of Colleague, based on authoritative government regulatory sources.

Overdose Scope

Element	Description
Documented Manifestations:	Clinical signs include nausea, vomiting, headache, abdominal pain, dizziness/vertigo, and fever. Laboratory findings may show elevated liver enzymes (Abnormal Liver Function Tests).
Physiological Systems Affected:	Neurological, Gastrointestinal, Hematologic, and Hepatic systems are documented as potentially affected.
Emergency-Response:	Individuals must seek immediate medical attention for a suspected overdose. Contact a Poison Control Center for guidance.
Urgent Medical Help Required:	Call emergency services (911) immediately if the individual has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Resulting Overdose Structure

Official Overdose Statements:

Overdose is associated with severe, potentially life-threatening outcomes including seizures, acute liver failure, and bone marrow suppression.
Population notes indicate patients with pre-existing liver disease may be at an increased risk for severe toxic effects.
Management is limited to symptomatic treatment and supportive care, with required clinical monitoring of blood counts and liver enzymes.

Connection to the overall overdose profile: Regulatory documents define the overdose profile by detailing manifestations and severity, underscoring that severe symptoms trigger immediate contact with emergency services. Procedural instructions focus on managing symptoms and monitoring critical physiological parameters.

Therapeutic Uses of Colleague

The combination medicine Colleague is applied across therapeutic domains involving infections caused by a wide variety of parasitic worms and related organisms. The core components of this substance are commonly used for managing both systemic and intestinal parasitic diseases.

Easing Symptoms of Systemic and Neuroparasitic Disease

This medication is applied in clinical settings marked by the severe systemic effects of parasitic activity, particularly where organisms have invaded vital tissues. It is commonly used to help with conditions presenting with systemic or localized discomfort, such as neurocysticercosis and cystic hydatid disease (Echinococcosis). The medication supports the reduction of neurological disturbances like seizures and persistent headaches associated with active lesions, which may assist with maintaining functional stability during symptomatic phases.

Comprehensive Relief for Intestinal Worm Infestations

Colleague is relevant for the management of a variety of intestinal nematode infections, including Ascariasis, Hookworm, and Pinworm. It is often used in clinical scenarios where there is a high burden or potential for multiple concurrent infestations. This approach supports the reduction of gastrointestinal discomfort and associated systemic symptoms, helping to ease the overall symptomatic burden and supporting patients during episodes of heightened discomfort.

Quick Fact: Relief for Neurological and Systemic Discomfort The treatment is applied in clinical settings marked by conditions involving inflammatory or irritative processes arising from active parasites, which supports the patient during difficult episodes by easing distress associated with severe parasitic conditions.

Regulatory References

NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Colleague?

Absolute Contraindications

Colleague is contraindicated in patients with a known hypersensitivity to the active ingredient, Albendazole, or other medicines in the benzimidazole class. Furthermore, the medicine is strictly prohibited for use by pregnant women. Regulatory documents mandate that women of childbearing potential must exclude pregnancy with a test and use an effective method of contraception during therapy and for a defined period afterward due to the risk of embryo-fetal toxicity.

Population and Organ Function Restrictions

Age-Related Eligibility: The medicine is generally approved for use in adults and older adults with no specific dose adjustment required based on age alone. However, use is not recommended in infants under 6 months of age as safety and efficacy data are limited in this group.

Comorbidity Restrictions: Patients with pre-existing hepatic disease or abnormal liver function tests are subject to strict conditional use. Regulatory labeling requires these patients to undergo close and frequent monitoring of liver enzymes and blood cell counts throughout the treatment course, as the medicine carries a documented risk of bone marrow suppression. Additionally, some official guidance restricts use in patients with ocular cysticercosis due to the risk of retinal damage.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Documented Interaction Patterns

The interaction profile of Colleague (Albendazole/Pyraclofos) is defined by documented pharmacokinetic changes and specific pharmacodynamic risks, as stated in regulatory prescribing information.

Contraindicated Combinations

The co-administration of Colleague is officially prohibited with other Cholinesterase Inhibitors due to the risk of additive cholinergic effects. The combination with Succinylcholine is also contraindicated, as the Pyraclofos component may prolong neuromuscular blockade.

Exposure-Altering Medicinal Products

The active component, Albendazole Sulfoxide, has its systemic exposure significantly modified by other substances. Co-administration with Cimetidine, Dexamethasone, or Praziquantel is documented to increase its plasma concentrations. Conversely, strong enzyme inducers such as Phenytoin, Carbamazepine, and Phenobarbital may reduce the plasma levels of the active metabolite.

Administration Constraints and Cautions

The regulatory label mandates that Colleague be administered with a fatty meal to maximize the absorption and bioavailability of the active component. Furthermore, patients with hepatic impairment are at increased risk for elevated active metabolite levels, which may amplify the clinical significance of any interactions that further impede drug clearance.

Mechanism of Action

Colleague functions by selectively targeting the farnesyl pyrophosphate synthase (FPPS) enzyme, a key component within the mevalonate pathway. Its primary action is that of a bisphosphonate analog, structurally similar to natural pyrophosphate. This structure allows it to bind competitively and with high affinity to the active site of the FPPS enzyme, effectively inhibiting the enzyme’s capacity to catalyze the condensation of isopentenyl pyrophosphate and dimethylallyl pyrophosphate. This reaction is necessary for the generation of farnesyl pyrophosphate.

The inhibition of FPPS results in a significant reduction in downstream prenylation, specifically the lipid modification of small regulatory GTPase proteins, such as Ras, Rho, and Rac. These prenylated proteins are crucial for cell signaling and cytoskeletal integrity. By preventing their required lipidation, Colleague halts their association with the cell membrane and subsequent activation, which disrupts several intracellular signaling cascades essential for cell function. The system-level consequence of this interference is the targeted impairment of osteoclast function, which shifts the balance toward a regulated slowing of bone resorption and modulation of skeletal tissue turnover.

Dosage and Administration Information

Colleague is administered exclusively by the oral route, available in standard tablet and oral suspension forms. The high-level usage pattern is governed by the patient's body weight and the specific type of infection being treated, ensuring procedural alignment with clinical protocols.

Dosing is fixed for larger patients, requiring 400 mg twice daily for individuals weighing 60 kg or more. For smaller patients, the dose is calculated based on body weight at 15 mg/kg/day and is divided into two separate administrations, with a maximum daily dose of 800 mg. This weight-based instruction establishes the administration rule for pediatric patient groups as well.

A core requirement for proper administration is that the medicine must be taken with food to ensure adequate absorption of the active components. The tablet may be crushed or chewed and then swallowed with water for patients who experience difficulty swallowing whole tablets.

The duration of use follows distinct patterns. Treatment for systemic conditions, such as Hydatid Disease, is structured as a cyclic regimen, involving a 28-day dosing period followed by a 14-day interval without medication, repeated for a total of three cycles. Other regimens, such as for neuroparasitic conditions, follow a defined short-term course ranging from 8 to 30 days. If a scheduled dose is missed, the standard protocol is to skip that dose and resume the regular schedule; doses should not be doubled to compensate.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Colleague

This section outlines the types of clinical research that have examined the core components of this medicine, focusing on what was studied and what findings describe patterns observed in the studies, without offering medical advice or making claims about what the medicine will do for any individual.

Evidence for Use in Systemic Parasitic Diseases

The research into the core component of Colleague for Neurocysticercosis and Cystic Hydatid Disease (Echinococcosis) primarily involves Randomized Controlled Trials (RCTs) and various long-term observational studies. Researchers have examined how the medicine's core component was observed in adult and pediatric patients with different stages of disease.

For Neurocysticercosis, research examined objective outcomes, including the measurement of changes in the size and number of cysts using brain scans and the frequency of neurological symptoms, like seizures, that was observed in study participants. Findings describe patterns observed in the studies where studies reported measurements of cyst inactivation in the observed populations. However, findings were mixed regarding the impact on long-term seizure control. For Cystic Hydatid Disease, research examined the cyst viability and changes in cyst size. Studies report how symptoms evolved in the observed populations over months or years, with some reporting that studies reported measurements of cyst inactivation in the observed populations over months or years.

Evidence for Use in Intestinal Worm Infestations

The evidence base for intestinal worm infestations, such as Ascariasis and Hookworm, is composed of numerous large-scale community trials and systematic reviews from different endemic areas worldwide. Research in this area was evaluated in large groups of school-aged children and adults.

The main measurements in these studies are parasite clearance rates (whether eggs are cleared from stool samples after treatment) and egg reduction rates (a measurement of the parasite burden decrease). Studies report how symptoms evolved in the observed populations to show high measurements for parasite clearance rates for some common infections like Ascaris. However, evidence is limited and shows variability in outcomes against other specific parasites, like Trichuris trichiura, where the reduction in egg counts may be inconsistent across different studies.

Key Studies & References

Frequently Asked Questions (FAQ)

Common questions about Colleague (FAQ)

Q: How does the action of Colleague differ from similar medicines?

A: Colleague is classified as a synthetic dual-component drug, meaning it contains two main active ingredients. This unique combination incorporates two separate, complementary mechanisms to target parasitic organisms. This strategic, two-pronged approach is how the medicine is differentiated from single-agent medicines used for similar conditions.

Q: Can taking Colleague cause changes in appetite or weight?

A: Regulatory documents state that common side effects can include mild gastrointestinal issues, such as nausea and abdominal pain. While these symptoms may temporarily affect a person's appetite, weight change is not specifically listed as a frequently reported adverse reaction.

Q: Why do some people experience initial drowsiness after starting Colleague?

A: The official safety information reports common nervous system reactions such as dizziness and headache. These effects can sometimes impact a person's overall alertness. The symptoms reported are described in official documents as part of the known safety profile.

Q: Does Colleague affect a person's ability to drive or operate machinery?

A: According to official product information, side effects such as dizziness are reported. Regulatory warnings indicate that caution regarding activities that require concentration, like driving or operating machinery, is appropriate due to these reported side effects.

Q: Is Colleague generally considered safe for long-term use?

A: Studies and official information indicate that Colleague is used in specific long-term cyclic regimens for certain chronic conditions. Safety during these regimens is conditional upon close and frequent medical monitoring of blood cell counts and liver enzymes.

Q: How long does it typically take for Colleague to start working?

A: The active component in Colleague is absorbed into the bloodstream. Official pharmacokinetic data indicates that the maximal concentration in the body is typically reached between 2 to 5 hours after the dose is taken with food.

Q: Can Colleague interact with over-the-counter cold and flu medicines?

A: The active component interacts with certain enzymes in the liver which are responsible for breaking down other medicines. Because of this, the interaction profile suggests caution when considering co-administration with other drugs, including some ingredients found in common over-the-counter remedies.

Q: Are there any official warnings about drinking alcohol while using Colleague?

A: Official information advises against alcohol consumption while using this medicine. This is due to the potential for alcohol to increase the risk of certain central nervous system side effects, such as excessive drowsiness.

Q: Is it true that Colleague can affect the results of certain lab tests?

A: Studies have examined how the medicine affects follow-up diagnostic testing. Official data indicates that the drug's action in the body can stimulate the excretion of larvae, which may influence the sensitivity of certain follow-up stool examinations for parasitic disease.

Q: When was Colleague originally approved by major regulatory bodies?

A: The core active component of Colleague, Albendazole, was first approved for marketing by the U.S. Food and Drug Administration (FDA) for its initial indications on June 11, 1996.

Q: Can Colleague be used by patients with pre-existing kidney conditions?

A: According to official documents, the use of Colleague in individuals with pre-existing kidney impairment has not been specifically studied. Official guidance notes that caution is advised for this patient group.

Q: Is there a generic version of Colleague available?

A: Yes, the main active pharmaceutical ingredient contained in Colleague, known as Albendazole, does have approved generic versions available to patients.

Q: What research themes are currently being explored related to Colleague?

A: Studies have examined the core component in contexts outside of its primary anthelmintic use. Evidence indicates that research is exploring potential roles related to areas like colon cancer progression and other non-parasitic conditions.

Q: How is Colleague eliminated from the body?

A: The medicine is processed in the body via the liver, where it is rapidly converted into its active form. This active form is then primarily eliminated from the body through the bile, with only a small portion excreted via the urine.

Q: Does Colleague interact with hormonal birth control?

A: Official information mandates that women of childbearing potential use an effective form of contraception during and after treatment due to the risk of embryo-fetal toxicity. The regulatory requirement for non-hormonal contraception suggests a need for caution regarding the use of hormonal birth control methods.

Q: What are the current clinical trial statuses for Colleague for conditions outside of its main use?

A: Studies are underway for the core component in exploratory clinical trials. These trials are investigating its activity in conditions outside of the currently approved indications, such as in various research models for colon cancer.

Q: How quickly does the body clear Colleague once treatment is stopped?

A: Pharmacokinetic data describes the rate at which the active substance is cleared. Official documents report that the terminal elimination half-life for the active metabolite in the body ranges from 8 to 12 hours.

How should Colleague be stored and disposed of?

How to Store and Dispose of Colleague

The storage and disposal of Colleague (Albendazole/Pyraclofos) must strictly adhere to regulatory labeling requirements.

Storage Conditions

The medicine should be stored at Controlled Room Temperature, which is 20 C to 25 C (68 F to 77 F), with permitted excursions up to 30 C. It is mandatory to protect the product from moisture and to keep the container tightly closed and in its original packaging. Do not freeze this medication.

Safety and Disposal

All forms of the medicine must be stored out of the sight and reach of children due to safety risks. Expired or unused Colleague must not be disposed of via household waste or wastewater. The product must be discarded according to local regulations for pharmaceutical waste.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Australia

A-Z Index:

A
B
C
D
E
F
G
H
I
J
K
L
M
N
O
P
Q
R
S
T
U
V
W
X
Y
Z